(Reuters) – AstraZeneca said on Monday it had finalised plans to divest its Crohn’s disease drug Entocort by selling U.S. rights to the medicine to Perrigo (PRGO.N) for $380 million.
The move is part of an “externalization” drive by the British drugmaker, which is selling non-core products to help it fill a short-term revenue gap caused by older products going off product, while investing in a pipeline of new medicines.
Entocort had U.S. sales of $89 million in the first nine months of 2015.
The deal, which is expected to complete by the end of 2015, follows AstraZeneca’s sale of rights to Entocort outside the United States in July to Tillotts Pharma, part of the Zeria Group.
AstraZeneca said its earnings per share outlook for the year, which was upgraded at third-quarter results earlier this month, would not change as a result of the Perrigo transaction.
(Reporting by Ben Hirschler; editing by Jason Neely)
Antibiotic resistance remains one of the biggest public health challenges. New drugs are still needed to tackle tough-to-treat bacteria. But finding new therapeutics to kill off pathogenic bacteria has been difficult.
Viral vectors are engineered viruses used to deliver gene therapies, gene-modified cell therapies and certain vaccines. And their shortage is already upon us, thanks to manufacturing approaches that simply haven’t kept pace with the advance of cell and gene therapies.
Beigene, a fast-growing drugmaker based in Cambridge, Massachusetts and Beijing, will partner with Shoreline Biosciences to develop cell therapies for cancer, expanding its research beyond the small molecule and antibody drugs.